Mendaera and Butterfly Network today announced that Mendaera’s Focalist system is now commercially available with Butterfly Network’s Ultrasound-on-Chip imaging technology.
Mendaera’s FDA-cleared Focalist system combines handheld robotics and guidance software to support image-guided needle procedures, including vascular access, regional nerve blocks and organ access.
“Ultrasound is fundamental to how Focalist sees and guides intervention, and Butterfly gives us a uniquely digital and programmable imaging platform to build on,” said Josh DeFonzo, co-founder and CEO of Mendaera, in a statement. “Bringing Butterfly into our commercial platform expands access to precise, image-guided intervention today, while its software-defined architecture opens a path toward AI-enabled image interpretation and robotic action.”
Butterfly and Mendaera first announced their collaboration through the Butterfly Embedded program, bringing together complementary imaging and robotics technologies.
“Mendaera is tackling a real problem in healthcare with a platform designed to expand access to procedural imaging, while reducing reliance on a limited group of highly specialized expertise,” said Joseph DeVivo, president, CEO and chairman at Butterfly Network, in a statement. “We’re proud that this milestone not only extends Butterfly’s commitment to democratizing medical imaging but also marks our first Butterfly Embedded partner to commercialize — bringing our vision to life and demonstrating what Ultrasound-on-Chip can enable beyond traditional ultrasound.”
